Literature DB >> 19480556

Application of multivariate statistical procedures to identify transcription factors that correlate with MRP2, 3, and 4 mRNA in adult human livers.

L M Aleksunes1, R L Yeager, C D Klaassen.   

Abstract

Multidrug resistance-associated proteins 2-4 (MRP2-4) are membrane efflux transporters critical for the hepatic clearance of pharmaceuticals and endogenous chemicals. Little is known about the constitutive regulation of MRP2-4 mRNA in normal human liver. The purpose of this study was to identify transcription factors whose expression significantly correlates with MRP2-4 mRNA in human liver specimens. Ninety adult human livers were profiled for mRNA expression of MRP2-4 as well as aryl hydrocarbon receptor (AhR), constitutive androstane receptor (CAR), pregnane X receptor (PXR), peroxisome proliferator-activated receptor alpha (PPAR alpha) and gamma (gamma), liver X receptor alpha (LXR alpha), farnesoid X receptor (FXR), glucocorticoid receptor (GR), retinoid X receptor alpha (RXR alpha), hepatocyte nuclear factor 1 alpha (HNF1 alpha) and 4 alpha (4 alpha), and nuclear factor E2-related factor 2 (Nrf2) transcription factors. Using linear regression and stepwise selection of partial R(2)-values, CAR, HNF1 alpha, and PPAR alpha mRNA exhibited the greatest correlation with MRP2, 3, and 4, respectively. Interindividual variation in the expression of the identified transcription factors may account for the variability in constitutive mRNA levels of MRP2-4. The multivariate approach presented in this study should aid in predicting signalling pathways that participate either directly or indirectly in regulating hepatic drug disposition.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19480556      PMCID: PMC2698955          DOI: 10.1080/00498250902952514

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  31 in total

Review 1.  Liver-enriched transcription factors in liver function and development. Part I: the hepatocyte nuclear factor network and liver-specific gene expression.

Authors:  Harald Schrem; Jürgen Klempnauer; Jürgen Borlak
Journal:  Pharmacol Rev       Date:  2002-03       Impact factor: 25.468

2.  Control of pancreas and liver gene expression by HNF transcription factors.

Authors:  Duncan T Odom; Nora Zizlsperger; D Benjamin Gordon; George W Bell; Nicola J Rinaldi; Heather L Murray; Tom L Volkert; Jörg Schreiber; P Alexander Rolfe; David K Gifford; Ernest Fraenkel; Graeme I Bell; Richard A Young
Journal:  Science       Date:  2004-02-27       Impact factor: 47.728

Review 3.  Liver-enriched transcription factors and hepatocyte differentiation.

Authors:  S Cereghini
Journal:  FASEB J       Date:  1996-02       Impact factor: 5.191

4.  The pregnane X receptor: a promiscuous xenobiotic receptor that has diverged during evolution.

Authors:  S A Jones; L B Moore; J L Shenk; G B Wisely; G A Hamilton; D D McKee; N C Tomkinson; E L LeCluyse; M H Lambert; T M Willson; S A Kliewer; J T Moore
Journal:  Mol Endocrinol       Date:  2000-01

5.  Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor.

Authors:  Heidi R Kast; Bryan Goodwin; Paul T Tarr; Stacey A Jones; Andrew M Anisfeld; Catherine M Stoltz; Peter Tontonoz; Steve Kliewer; Timothy M Willson; Peter A Edwards
Journal:  J Biol Chem       Date:  2001-11-12       Impact factor: 5.157

6.  Induction of bilirubin clearance by the constitutive androstane receptor (CAR).

Authors:  Wendong Huang; Jun Zhang; Steven S Chua; Mohammed Qatanani; Yunqing Han; Riccarda Granata; David D Moore
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-18       Impact factor: 11.205

7.  Identification and functional characterization of the natural variant MRP3-Arg1297His of human multidrug resistance protein 3 (MRP3/ABCC3).

Authors:  Young-Min A Lee; Yunhai Cui; Jörg König; Angela Risch; Birgit Jäger; Peter Drings; Helmut Bartsch; Dietrich Keppler; Anne T Nies
Journal:  Pharmacogenetics       Date:  2004-04

Review 8.  Role of orphan nuclear receptors in the regulation of drug-metabolising enzymes.

Authors:  Hongbing Wang; Edward L LeCluyse
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

9.  Alternatively spliced isoforms of the human constitutive androstane receptor.

Authors:  Scott S Auerbach; Richard Ramsden; Matthew A Stoner; Christophe Verlinde; Christopher Hassett; Curtis J Omiecinski
Journal:  Nucleic Acids Res       Date:  2003-06-15       Impact factor: 16.971

10.  The transactivation potential of variant hepatocyte nuclear factor 1 is modified by alternative splicing.

Authors:  F Ringeisen; J Rey-Campos; M Yaniv
Journal:  J Biol Chem       Date:  1993-12-05       Impact factor: 5.157

View more
  12 in total

Review 1.  Sandwich-cultured hepatocytes: an in vitro model to evaluate hepatobiliary transporter-based drug interactions and hepatotoxicity.

Authors:  Brandon Swift; Nathan D Pfeifer; Kim L R Brouwer
Journal:  Drug Metab Rev       Date:  2010-08       Impact factor: 4.518

Review 2.  Multiple drug resistance-associated protein 4 (MRP4), prostaglandin transporter (PGT), and 15-hydroxyprostaglandin dehydrogenase (15-PGDH) as determinants of PGE2 levels in cancer.

Authors:  Tyler J Kochel; Amy M Fulton
Journal:  Prostaglandins Other Lipid Mediat       Date:  2014-11-27       Impact factor: 3.072

3.  Nrf2 Ameliorates DDC-Induced Sclerosing Cholangitis and Biliary Fibrosis and Improves the Regenerative Capacity of the Liver.

Authors:  Athanassios Fragoulis; Julia Schenkel; Miriam Herzog; Tim Schellenberg; Holger Jahr; Thomas Pufe; Christian Trautwein; Thomas W Kensler; Konrad L Streetz; Christoph Jan Wruck
Journal:  Toxicol Sci       Date:  2019-06-01       Impact factor: 4.849

4.  Transcriptional regulation of renal cytoprotective genes by Nrf2 and its potential use as a therapeutic target to mitigate cisplatin-induced nephrotoxicity.

Authors:  Lauren M Aleksunes; Michael J Goedken; Cheryl E Rockwell; Juergen Thomale; Jose E Manautou; Curtis D Klaassen
Journal:  J Pharmacol Exp Ther       Date:  2010-07-06       Impact factor: 4.030

5.  Coordinated regulation of hepatic phase I and II drug-metabolizing genes and transporters using AhR-, CAR-, PXR-, PPARα-, and Nrf2-null mice.

Authors:  Lauren M Aleksunes; Curtis D Klaassen
Journal:  Drug Metab Dispos       Date:  2012-04-11       Impact factor: 3.922

6.  Alcohol cirrhosis alters nuclear receptor and drug transporter expression in human liver.

Authors:  Vijay R More; Qiuqiong Cheng; Ajay C Donepudi; David B Buckley; Zhenqiang James Lu; Nathan J Cherrington; Angela L Slitt
Journal:  Drug Metab Dispos       Date:  2013-03-05       Impact factor: 3.922

Review 7.  Xenobiotic, bile acid, and cholesterol transporters: function and regulation.

Authors:  Curtis D Klaassen; Lauren M Aleksunes
Journal:  Pharmacol Rev       Date:  2010-01-26       Impact factor: 25.468

Review 8.  Mechanisms of activation of the transcription factor Nrf2 by redox stressors, nutrient cues, and energy status and the pathways through which it attenuates degenerative disease.

Authors:  Lauren E Tebay; Holly Robertson; Stephen T Durant; Steven R Vitale; Trevor M Penning; Albena T Dinkova-Kostova; John D Hayes
Journal:  Free Radic Biol Med       Date:  2015-06-27       Impact factor: 7.376

9.  Sex-, Age-, and Race/Ethnicity-Dependent Variations in Drug-Processing and NRF2-Regulated Genes in Human Livers.

Authors:  Jie Liu; Julia Yue Cui; Yuan-Fu Lu; J Christopher Corton; Curtis D Klaassen
Journal:  Drug Metab Dispos       Date:  2020-11-08       Impact factor: 3.922

10.  Aspirin influences megakaryocytic gene expression leading to up-regulation of multidrug resistance protein-4 in human platelets.

Authors:  Isabella Massimi; Raffaella Guerriero; Lavinia Vittoria Lotti; Valentina Lulli; Alessandra Borgognone; Federico Romani; Francesco Barillà; Carlo Gaudio; Marco Gabbianelli; Luigi Frati; Fabio M Pulcinelli
Journal:  Br J Clin Pharmacol       Date:  2014-12       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.